Decheng Capital Global Life Sciences Fund IV, L.P. - Feb 14, 2025 SCHEDULE 13G Report for Aardvark Therapeutics, Inc. Common Stock, par value $0.00001 per share

Filing Manager
Decheng Capital Global Life Sciences Fund IV, L.P.
Reporting Manager
Xiangmin Cui
Security
Aardvark Therapeutics, Inc. Common Stock, par value $0.00001 per share
Shares outstanding
21.4M shares
Disclosed Ownership
3.92M shares
Ownership
18.3%
Form type
SCHEDULE 13G
Date filed
2/24/2025, 04:16 PM
Date of event
Feb 14, 2025
SEC
View on sec.gov

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Decheng Capital Global Life Sciences Fund IV, L.P. 13.8% 2.96M 0 2.96M /s/ Xiangmin Cui By Decheng Capital Management IV (Cayman), LLC, its General Partner, By Xiangmin Cui, Manager
Decheng Capital Management IV (Cayman), LLC 13.8% 2.96M 0 2.96M /s/ Xiangmin Cui By Xiangmin Cui, Manager
Decheng Capital Global Healthcare Fund (Master), LP 4.5% 958K 0 958K /s/ Xiangmin Cui By Decheng Capital Global Healthcare GP, LLC, its General Partner, By Decheng Capital LLC, its Manager, By Xiangmin Cui, Manager
Decheng Capital Global Healthcare GP, LLC 4.5% 958K 0 958K /s/ Xiangmin Cui By Decheng Capital LLC, its Manager, By Xiangmin Cui, Manager
Xiangmin Cui 18.3% 3.92M 0 3.92M /s/ Xiangmin Cui Xiangmin Cui